At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 7,539 enrolled
Drug / intervention
Herpes Zoster Vaccine GSK1437173Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy, Safety and Immunogenicity of GSK Biologicals' HZ/su Vaccine GSK1437173A in a Phase IIIb, Open-label, Long-term Follow-up Study (ZOE-LTFU) of Studies 110390/113077 (ZOSTER-006/022) and Assessment of Additional Doses in Older Adults
In Brief
A Phase 3 clinical trial evaluating Herpes Zoster Vaccine GSK1437173A for Herpes Zoster and Herpes Zoster Vaccine. Completed, enrolled 7,539 participants across 161 sites in 18 countries.
Detailed Summary
The purpose of this study was a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and included an assessment of 1 or 2 additional doses in two subgroups of older adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster, Herpes Zoster Vaccine
CountriesAustralia, Brazil, Canada, Czechia, Estonia, Finland, France, Germany, Hong Kong, Italy, Japan, Mexico, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionJun 2023
Study CompletionJan 2024
TodayJul 2026
First PostedMar 30, 2016
Enrollment StartApr 16, 2016
Primary CompletionJun 28, 2023
Study CompletionJan 30, 2024
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 10.3 years ago
Interventions
Herpes Zoster Vaccine GSK1437173Abiological
Intramuscular injection